-+ 0.00%
-+ 0.00%
-+ 0.00%

Galmed, Tel Aviv University to study Aramchol in metastatic brain cancer

PUBT·04/14/2026 11:35:46
Listen to the news
Galmed, Tel Aviv University to study Aramchol in metastatic brain cancer
  • Galmed Pharmaceuticals entered a research collaboration with Ramot at Tel Aviv University to evaluate Aramchol as a targeted therapy for metastatic brain cancer.
  • Results have not yet been presented; work will generate new preclinical findings intended to support clinical development.
  • Collaboration aims to validate whether Aramchol can curb growth of p53-deficient brain metastases by targeting a metabolic dependency linked to SCD1.
  • Program also positions Aramchol for broader oncology development, with Galmed citing ongoing clinical work at Virginia Commonwealth University in colorectal cancer where p53 mutations are common.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.